Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Optimizing Cough Rehabilitation Through Combined Cough Skill Training and Transcutaneous Spinal Cord Stimulation (Optimizing Cou)

17. november 2026 opdateret af: University of Florida

The goal of this clinical trial is to evaluate the effects of combining cough training with low-level electrical stimulation to the neck (tsDCS) in healthy adults and adults with neurological diseases. The main questions it aims to answer are:

  • Is using tsDCS during cough training safe, tolerable, and acceptable to participants?
  • What tsDCS settings are most effective for pairing with cough training? Researchers will compare sham stimulation with active tsDCS to see if tsDCS enhances cough gains. Before and after each testing session, participants will complete breathing, coughing, and respiratory-strength training.

Studieoversigt

Detaljeret beskrivelse

Study Purpose and Background People with neurodegenerative diseases frequently experience reduced cough function (hypotussia) and swallowing difficulties (dysphagia), which negatively impact quality of life and increase the risk of pneumonia, a leading cause of death in these populations. While behavioral exercises like cough training can help improve airway protection, people with these diseases often struggle to perform them with the high intensity required to trigger lasting brain and nerve adaptation (neuroplasticity).

To overcome this limitation, this pilot study investigates a novel, non-invasive combinatorial approach: pairing Cough Skill Training (CST) with transcutaneous spinal direct current stimulation (tsDCS) applied to the neck. The theory is that spinal stimulation enhances communication between the brain and muscles, optimizing the outcomes of training. Because this combined intervention has not been tested before, this initial research aims to establish its overall feasibility and compare different stimulation settings in healthy adults before future translation to clinical patient populations.

Study Design and Methods This study is an initial pilot trial utilizing a randomized crossover design involving 16 healthy adult participants aged 40 to 85 years with normal respiratory function.

  • Screening & Familiarization (Visit 1): Participants undergo baseline screening, including health history reviews and spirometry (pulmonary function testing). They are also familiarized with the testing and training activities.
  • Intervention Sessions: Across separate intervention visits separated by a 6-week washout period, participants receive 20 minutes of neck-based tsDCS paired with CST. During active stimulation, current is delivered continuously, whereas sham stimulation provides brief ramping periods without sustained current. CST involves visual feedback on a computer screen to guide participants through coughing at specific target ranges (strong, moderate, and weak).
  • Assessments: Researchers record vital signs, breathing tests, airway occlusions (to measure drive to breathe), maximum respiratory pressure tests. Exploratory measures, such as saliva swallowing patterns and how long participants can produce a vowel sound, are also tracked.

Aims:

  • Aim 1: Feasibility and acceptability will be evaluated by the participants' ability to complete all training tasks simultaneously with stimulation, scores from the Acceptability of Intervention Measure (AIM), participant ability to blind/detect sham versus active treatment, and perceived exertion, task difficulty, and stimulation intensity ratings.
  • Aim 2: Cough and respiratory performance will be measured by the change in cough peak expiratory flow rate (PEFR) from baseline, along with CST performance accuracy, other cough, resting breathing, and respiratory strength parameters.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

16

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: May Smith-Hublou, PhD, SLP
  • Telefonnummer: 352-273-6855
  • E-mail: maysmith@ufl.edu

Undersøgelse Kontakt Backup

  • Navn: Barbara K Smith, PhD, PT
  • Telefonnummer: 352-294-5315

Studiesteder

    • Florida
      • Gainesville, Florida, Forenede Stater, 32610
        • University of Florida
        • Kontakt:
        • Ledende efterforsker:
          • May Smith-Hublou, PhD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

40 år til 85 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Forced vital capacity (FVC) ≥ 80% predicted based on age/sex

Exclusion Criteria:

  • neurological disease
  • respiratory disease including acute respiratory infection with cough during past week
  • Pregnancy
  • metallic implants in the spine
  • cardiac pacemaker
  • use of sodium channel blockers, calcium channel blockers, and/or NMDA receptor antagonists

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Sham-komparator: Sham Stimulation

Transcutaneous spinal cord stimulation at reduced intensity, lasting 1 minute at the beginning and end of a 20-minute session.

CST involves visual feedback on a computer screen to guide participants through coughing at specific target ranges (strong, moderate, and weak).

Transcutaneous spinal cord stimulation at reduced intensity, lasting 1 minute at the beginning and end of a 20-minute session.

Eksperimentel: Cathodal Stimulation

Transcutaneous spinal cord stimulation at 2mA intensity, for 20 minutes.

CST involves visual feedback on a computer screen to guide participants through coughing at specific target ranges (strong, moderate, and weak).

Transcutaneous spinal cord stimulation at 2mA intensity, for 20 minutes.

Eksperimentel: Anodal Stimulation

Transcutaneous spinal cord stimulation at 2mA intensity, for 20 minutes.

CST involves visual feedback on a computer screen to guide participants through coughing at specific target ranges (strong, moderate, and weak).

Transcutaneous spinal cord stimulation at 2mA intensity, for 20 minutes.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Completion of training tasks with simultaneous stimulation
Tidsramme: During training

Measured as percentage of sessions in which both interventions can be completed simultaneously.

During training
Peak Cough Flow
Tidsramme: Baseline, immediate post-single-treatment measurement

The highest rate of airflow generated during a volitional cough

Baseline, immediate post-single-treatment measurement

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Acceptability of Intervention Measure (AIM)
Tidsramme: Immediate post-single-treatment measurement

Participants will rate favorability of treatment procedures. This scale consists of 4 items rating acceptability using a 1-5 Likert Scale, with a combined total score range of 4-20. A score of 1 represents "completely disagree," and a score of 5 represents "completely agree." Thus, a higher score reflects a more favorable experience.

Immediate post-single-treatment measurement

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Airway occlusion pressure (P0.1)
Tidsramme: Baseline vs immediate post-single-treatment

The change in air pressure at the opening of the airway (mouth and nose) in the first 100 ms of a breath. This estimates neural drive to breathe.

Baseline vs immediate post-single-treatment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: May Smith-Hublou, PhD, University of Florida

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. december 2026

Primær færdiggørelse (Anslået)

30. september 2027

Studieafslutning (Anslået)

31. december 2027

Datoer for studieregistrering

Først indsendt

15. oktober 2026

Først indsendt, der opfyldte QC-kriterier

17. november 2026

Først opslået (Faktiske)

18. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

17. november 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Participant data that underlie the results reported in this article after deidentification.

IPD-delingstidsramme

9 months and ending 36 months following article publication.

IPD-delingsadgangskriterier

Investigators whose proposed use of the data has been approved by an independent review committee.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner